Global change assessments in anti-Alzheimer clinical drug trials

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The assessment of efficacy in clinical trials in Alzheimer's disease has been a controversial area. The US Food and Drug Administration has not accepted mental status assessment as a sole determinant of efficacy because of concerns about oversensitivity and lack of direct linkage to clinical importance. Global change instruments offer a number of advantages as primary outcome measures, chief among which is a wide range of responsiveness, a property well suited for trials of 1 to 2 years. Initial investigations with global change instruments have shown encouraging validity. Reliability has been only moderate, suggesting that the methodology needs further attention. A standardized format for interview and the acceptance of a set of anchor points that better define the ratings of change are two modifications that should improve reliability. Global change instruments, if properly explained to the patients, caregivers and primary physicians, will capture the concept of clinical importance.

Original languageEnglish (US)
Pages (from-to)8-15
Number of pages8
JournalDementia and geriatric cognitive disorders
Volume9
Issue numberSUPPL. 3
DOIs
StatePublished - Oct 1998

Keywords

  • Alzheimer's disease
  • Clinical trials
  • Functional assessments
  • Global change ratings
  • Mental status examinations

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Cognitive Neuroscience
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Global change assessments in anti-Alzheimer clinical drug trials'. Together they form a unique fingerprint.

  • Cite this